Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dopamine receptor pharmacology

P Seeman1, H H Van Tol

  • 1Department of Pharmacology, University of Toronto, Ontario, Canada.

Trends in Pharmacological Sciences
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patients.

Scientific reports·2021
Same author

Demyelinating Charcot-Marie-Tooth neuropathy associated with FBLN5 mutations.

European journal of neurology·2020
Same author

Novel SBF2 mutations and clinical spectrum of Charcot-Marie-Tooth neuropathy type 4B2.

Clinical genetics·2018
Same author

Charcot-Marie-Tooth 1A: Heterozygous T118M Mutation over a CMT1A Duplication Has No Influence on the Phenotype.

Annals of the New York Academy of Sciences·2017
Same author

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.

Translational psychiatry·2016
Same author

HSMNR belongs to the most frequent types of hereditary neuropathy in the Czech Republic and is twice more frequent than HMSNL.

Clinical genetics·2016

Dopamine receptor subtypes are key targets for treating neurological disorders. Targeting dopamine D4 receptors may lead to more effective antipsychotic drugs for schizophrenia.

Area of Science:

  • Neuropharmacology
  • Molecular Psychiatry

Background:

  • Dopamine receptors are crucial targets for treating schizophrenia, Parkinson's disease, and Huntington's chorea.
  • Current therapies often target D2 receptors, but clozapine's preference for D4 receptors suggests subtype selectivity is important.
  • D1 and D2 receptor interactions, potentially mediated by G proteins, influence therapeutic outcomes.

Purpose of the Study:

  • To review the role of dopamine receptor subtypes in neurological disorders.
  • To explore the potential of selective dopamine receptor subtype targeting for improved therapies.
  • To highlight dopamine D4 receptors as a promising target for future antipsychotic drug development.

Main Methods:

  • Review of existing literature on dopamine receptor pharmacology and clinical applications.

Related Experiment Videos

  • Analysis of receptor binding affinities and clinical potencies of antipsychotic drugs.
  • Examination of dopamine receptor density changes in schizophrenia.

    • Main Results:

    • Most antipsychotics correlate with D2 receptor blockade, but clozapine uniquely targets D4 receptors.
    • Schizophrenia shows elevated D2 and D3 receptor density (10%) and significantly elevated D4 receptor density (600%).
    • The discovery of five cloned dopamine receptors aids in developing selective drugs.

    Conclusions:

    • Selective targeting of dopamine receptor subtypes, particularly D4, offers potential for enhanced antipsychotic and antiparkinsonian therapies.
    • Understanding dopamine receptor subtypes is critical for advancing treatments for major neurological and psychiatric disorders.
    • Cloned dopamine receptors are instrumental in the discovery of novel, selective therapeutic agents.